What Vivolight does

Vivolight is a privately held Chinese medical device company founded in 2012 and headquartered in Shenzhen, with a dedicated R&D base (Vivolight Research Institute) established in 2021 in Xi'an. The company is incubated from the Chinese Academy of Sciences and develops minimally invasive laser diagnostic and therapeutic technologies for cardiovascular and peripheral vascular disease. Its product platform spans three integrated pillars: (1) intravascular OCT imaging systems (Cornaris P60/P80) with proprietary pencil-beam all-fiber OCT catheters (Pathfinder164, 0.86mm outer diameter, up to 12,000 rpm rotation); (2) a 355nm triple-frequency Nd:YAG cold laser plaque ablation system for peripheral arterial disease; and (3) portable infrared vein imaging devices (PVF V800). An AI software layer overlays these devices, including OCT-FFR (CFD + deep learning coronary flow computation), ICA (Intelligent Calcium Assessment, multi-scale multi-task u-net), IPA (Index of Plaque Attenuation), and CA-GPT — an LLM-based coronary intervention AI agent. The company reports full in-house control of laser, fiber-optic catheter, and image-processing core technologies.

Vivolight monetizes primarily through capital equipment sales (OCT systems), recurring consumables (OCT imaging catheters), and software licensing, sold via direct enterprise sales to tertiary hospitals through procurement tenders in China, and through direct sales channels internationally in 10+ countries. OCT products are deployed in 300+ Chinese hospitals, while the vein imaging device is distributed in 100+ countries. Customers are healthcare providers — primarily cardiovascular and peripheral vascular intervention departments of tertiary (Class III) hospitals and academic medical centers. The company has established clinical research collaborations with numerous top Chinese hospitals (e.g., Fuwai Hospital, Xuanwu Hospital, PLA General Hospital, Zhejiang University Second Hospital, Fudan Zhongshan Hospital, Xi'an Jiaotong University First Affiliated Hospital) and a Boston Scientific strategic alliance for internationalization.

The company has raised strategic capital from Sequoia China, Matrix Partners China, Fujian Capital, CAS Star, and others across multiple rounds, with a June 2026 round of "several hundred million RMB" co-led by Sino-US Green Yangtze Delta and Yifeng Capital earmarked for global commercialization and innovation pipeline. The company achieved break-even in 2025 and reports 100% overseas growth, with a domestic OCT market share position of #2 (and #1 among domestic brands) capturing approximately 1/4 of the Chinese coronary OCT market.

Name

Vivolight

Legal name

深圳市中科微光医疗器械技术有限公司

Website

https://vivolight.cn

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Vivolight is a Chinese medical device company founded in 2012 that develops intravascular OCT imaging systems, 355nm laser plaque ablation devices, and AI-enabled cardiovascular diagnostic software for tertiary hospitals in China and 10+ international markets.

Ownership category

akta.pro rank

Product category

Intravascular Imaging and Interventional Cardiology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Intravascular imaging devices
• Coronary OCT systems
• Laser ablation devices
• Vascular imaging catheters
• Cardiovascular intervention systems

Headquarters

HQ city

Nanshanqu

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. OCT影像系统及导管耗材销售: 销售泛血管OCT影像系统、配套成像导管耗材及软件，提供给国内及海外医院客户。属于高单价医疗器械硬件+专有耗材的捆绑销售模式。
2. 激光消融系统及耗材销售: 355nm冷激光斑块消融系统及配套耗材销售，面向冠脉及外周血管复杂病变治疗。
3. 血管成像仪销售: 便携式红外静脉血管成像仪（vein finder）等产品，销售覆盖国内及海外市场。

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Vivolight develops, manufactures, and sells minimally invasive laser-based diagnostic and therapeutic medical devices for cardiovascular and peripheral vascular intervention. Its portfolio centers on three platforms: panvascular OCT (Optical Coherence Tomography) imaging systems with proprietary catheters and AI software, a 355nm cold laser plaque ablation system, and a portable infrared vein imaging device. The company is among the few that independently master laser medicine, fiber-optic catheter, and image-processing technologies end-to-end.

Product overview

微光医疗 (Vivolight) is a medical device company focused on minimally invasive laser diagnostic and therapeutic technologies. The portfolio consists of three integrated pillars: (1) Diagnostic imaging — the Cornaris OCT imaging system (P60/P80) with compatible Pathfinder164 OCT catheters and ICA (Intelligent Calcium Assessment) AI software; (2) Functional assessment — the OCT-FFR software providing coronary blood flow fraction analysis from OCT images; and (3) Therapeutic intervention — the 355nm Cold Laser Plaque Ablation System (CLA) for peripheral vascular disease. An AI layer is provided by the CA-GPT (麒光 AI-OCT) AI-PCI system, which generates surgical decision recommendations from OCT data. Supporting products include the PVF V800 infrared vein imaging device and the Cornaris mobile app. The company positions itself as a 'diagnostic-therapeutic integration' hard-tech platform covering cardiovascular, peripheral vascular, and multi-vascular disease areas.

Differentiator

Problem solved

Functional benefit

Brands

• Cornaris APP: Mobile application for Cornaris system users

Products and services

• Cornaris P60/P80 OCT Imaging System Panvascular Optical Coherence Tomography imaging system providing high-resolution intravascular imaging of coronary and peripheral vessels, used in catheterization labs and vascular intervention procedures.
• Pathfinder164 OCT Imaging Catheter Single-use intravascular OCT imaging catheter based on Vivolight's proprietary pencil-beam full-fiber design, used with Cornaris OCT imaging systems for coronary and peripheral vessel scanning.
• OCT-FFR Software (Coronary OCT Quantitative Blood Flow Fraction Calculation Software) Software that derives coronary Fractional Flow Reserve (FFR) values from OCT pullback images using computational fluid dynamics and deep learning, eliminating the need for additional pressure wires or drugs during PCI.
• 355nm Cold Laser Plaque Ablation System (CLA) Triple-frequency Nd:YAG laser system using nanosecond-level cold ablation to precisely dissolve plaques in peripheral arterial disease while protecting normal vessel walls. Marketed for coronary and peripheral vascular complex lesions.
• CA-GPT (Jiguang AI-OCT) AI-PCI Coronary Intervention System LLM-based AI agent that ingests OCT imaging data combined with Chinese clinical guidelines and expert consensus to recommend PCI strategy, stent/drug-coated balloon sizing, and surgical risk prediction.
• PVF V800 Portable Infrared Vein Imaging Device (Vein Finder) Portable near-infrared vein finder that displays subcutaneous vein patterns in real time on the skin surface, assisting clinicians with venipuncture and IV placement in difficult populations such as children, elderly, and obese patients.

Quantifiable outcome

• OCT-FFR诊断准确率达98.0%，相关系数R=0.83（vs 传统FFR金标准压力导丝）
• +5 more outcomes

Named customers13 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature7 records

Partnerships

18 partnerships are on record, tiered core, major and minor.

• 波士顿科学 (Boston Scientific)coreStrategic or Co-development Partner微光医疗与波士顿科学达成战略合作，开中外合作之先河，是公司国际化战略的重要组成部分。波士顿科学是全球领先的微创医疗器械公司，此次合作旨在推动微光医疗产品的全球市场拓展和技术交流。
• 哈尔滨工业大学（深圳）majorStrategic or Co-development Partner联合哈尔滨工业大学（深圳）孙云旭副教授课题组共同研发pencil-beam全光纤OCT导管技术，该技术论文发表于Opto-Electronic Advances (IF=9.6)，得到国家自然科学基金及深圳市科技计划项目支持。
• 香港大学majorStrategic or Co-development Partner联合香港大学黄建业教授课题组共同研发pencil-beam全光纤OCT导管技术，三方产学研医工结合的成功案例。
• 哈佛医学院 Gary Tearney教授团队majorTechnology or Integration2017年CEO朱锐博士拜访全球腔内OCT技术创始人Gary Tearney教授，并斥资300万人民币获得OCT-FFR一体化硬件导管专利授权，后因工程化稳定性问题未落地，但开启了微光OCT-FFR技术方向的探索。
• 首都医科大学宣武医院coreStrategic or Co-development Partner郭连瑞教授、郭建明教授牵头，联合多家中心开展355nm冷激光多中心RCT研究，成果发表于JACC: Cardiovascular Interventions（IF=11.4）。
• 上海交通大学医学院附属第九人民医院coreStrategic or Co-development Partner作为多中心RCT研究参与单位，共同开展355nm冷激光斑块消融系统临床研究。
• 广东省人民医院coreStrategic or Co-development Partner作为多中心RCT研究参与单位，共同开展355nm冷激光斑块消融系统临床研究。
• 复旦大学附属中山医院coreStrategic or Co-development Partner李晨光教授参与OCT-FFR算法优化验证；牵头推进AI-OCT在喀什二院试点；是AI-OCT多中心临床试验核心参与单位。
• 空军军医大学唐都医院coreStrategic or Co-development Partner李妍教授、马文帅教授开展钙化体积预测支架膨胀研究；是AI-OCT多中心临床试验参与单位，发表CA-GPT研究成果。
• 北京安贞医院majorStrategic or Co-development PartnerAI-OCT多中心临床试验参与单位。
• 中国医学科学院阜外医院majorStrategic or Co-development PartnerAI-OCT多中心临床试验参与单位。
• 西安交通大学第一附属医院coreStrategic or Co-development Partner袁祖贻院长支持OCT-FFR 53例验证试验；355nm冷激光RCT研究参与单位；AI-OCT多中心临床试验参与单位。
• 浙江大学医学院附属第二医院coreStrategic or Co-development Partner王建安院士亲自牵头OCT-FFR注册临床研究（210例入组），蒋峻主任完成首例入组，倪骋教授在ESC年会汇报研究成果。
• 温州医科大学附属第一医院coreStrategic or Co-development PartnerOCT-FFR注册临床研究参与单位（4家顶尖临床机构之一）。
• 温州市医科大学附属第二医院coreStrategic or Co-development PartnerOCT-FFR注册临床研究参与单位（4家顶尖临床机构之一）。
• 上海市同济医院coreStrategic or Co-development PartnerOCT-FFR注册临床研究参与单位（4家顶尖临床机构之一）。
• 吉林心脏病医院majorStrategic or Co-development PartnerFrancesco Lavarra、Vasile Sirbu教授合作开展DK Crush边支优化OCT评估研究，成果发表于Frontiers in Cardiovascular Medicine (IF=6.05)。
• 欧洲分叉俱乐部 (European Bifurcation Club)minorStrategic or Co-development PartnerVasile Sirbu教授为欧洲分叉俱乐部会员(EBC)，参与合作开展DK Crush相关OCT研究。

Scale indicators9 records

Recent moves2 records

Broad incumbents

• Boston Scientific: Global interventional cardiology leader and Vivolight's announced strategic partner. Competes in intravascular imaging (IVUS) and complementary physiology/structural heart devices; partnership is a channel accelerant but also a competitive variable.
• MicroPort Scientific: Chinese medical device conglomerate with broad cardiovascular franchise including stents, balloon catheters, and emerging imaging assets. A domestic peer and potential competitor for hospital cardiology budgets and regulatory resources.
• Philips: Through its IGT business (formerly Volcano), Philips offers IVUS, physiology (PressureWire/Instant Wave-Free Ratio), and laser atherectomy — directly competing with Vivolight's OCT, OCT-FFR, and 355nm laser ablation products.

Emerging players

• Conavi Medical: Canadian developer of the Novasight Hybrid System combining IVUS and OCT in a single catheter. Overlaps with Vivolight's multi-modal OCT positioning and coronary imaging catheter portfolio.
• HeartFlow: US company commercializing FFR-CT, a non-invasive CT-derived fractional flow reserve. Indirect competitor for Vivolight's OCT-FFR — both target reducing invasive FFR procedures but use different imaging modalities.

Direct peers

• Terumo: Japanese medical device major offering LUNAWAVE OFDI (optical frequency domain imaging) for intravascular imaging. Directly competes with Vivolight's high-resolution coronary OCT platform in Asia and global markets.
• Ra Medical Systems: US-based developer of laser atherectomy catheters (previously the DABRA/Clirpath systems). Direct competitor to Vivolight's 355nm cold laser plaque ablation system in the peripheral vascular disease market.
• Opsens: Canadian developer of the OptoWire FFR wire and SavvyWire structural heart product. Competes in the physiology/intracoronary measurement space that Vivolight's OCT-FFR aims to disrupt.
• CathWorks: Israeli medical device company commercializing the FFRangio system, which computes FFR non-invasively from angiography. Directly competes with Vivolight's OCT-FFR concept of replacing pressure-wire FFR with image-derived physiology.
• Abbott: Global intravascular imaging leader with the ILUMIEN OPTIS OCT platform and Dragonfly catheters. Direct competitor to Vivolight's Cornaris OCT system in coronary and peripheral imaging; the benchmark Vivolight measured against in its head-to-head OCT comparison.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivolight